Fosavance
alendronic acid
colecalciferol
Osteoporosis, Postmenopausal
Date of authorisation:
Revision: 28
Last updated:
MedicineHumanAuthorised
Adrovance
alendronic acid
colecalciferol
Osteoporosis, Postmenopausal
Date of authorisation:
Revision: 26
Last updated:
MedicineHumanAuthorised
EMEA-002027-PIP02-17-M01 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Infectious diseases
PIP number: P/0340/2019
Route(s) of administration: Intramuscular use
Pharmaceutical form(s):
Suspension for injection
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-002553-PIP01-19 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Other
PIP number: P/0182/2019
Route(s) of administration: Oral use
Pharmaceutical form(s):
Film-coated tablet
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Pharmaceutics International Inc. - referral
sodium phenylbutyrate
progesterone
dutasteride
colecalciferol
Article 31 referrals
Status: European Commission final decision
Opinion/position date:
EC decision date:
Last updated:
ReferralHuman
Issarlos
Date of withdrawal:
Last updated:
MedicineHumanWithdrawn application